Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sushanth Jeyakumar

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Infectious Diseases and Therapy|May 24, 2023
Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care ResourcesLianne Barnieh, Rachel Beckerman, Sushanth Jeyakumar, et al.
Journal of Comparative Effectiveness Research|February 6, 2024
Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in GreeceEmmanouil Sinakos, Nandita Kachru, Christos Tsoulas, et al.
Journal of Medical Economics|April 27, 2021
Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare populationDeborah A Fisher, Jordan J Karlitz, Sushanth Jeyakumar, et al.
Journal of Medical Economics|February 23, 2026
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United StatesAndrea Lopez, Michael Gargano, Hongbo Yang, et al.
Journal of Medical Economics|April 9, 2026
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent <b><i>β</i></b>-thalassemia in the United StatesChuka Udeze, Michael Gargano, Hongbo Yang, et al.
MDM Policy & Practice|March 31, 2025
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in TaiwanElise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, et al.
Pain Medicine (Malden, Mass.)|April 22, 2026
Real World Treatment Patterns Among Patients with Painful Diabetic Peripheral Neuropathy in the United StatesNathaniel M Schuster, Sushanth Jeyakumar, Ann M Menzie, et al.
Scientific Reports|June 10, 2022
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysisRachel Beckerman, Andrea Gori, Sushanth Jeyakumar, et al.
Journal of Medical Economics|December 18, 2025
Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for painJeromie M Ballreich, Sushanth Jeyakumar, Kenna Garrison, et al.
Journal of Medical Economics|May 5, 2026
The incidence of opioid use disorder among people with acute and chronic pain managed with prescription opioids in the United States: economic and societal burdenAndrew J Schoenfeld, Sushanth Jeyakumar, Jessica Morlando Geiger, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Infectious Diseases and Therapy|May 24, 2023
Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care ResourcesLianne Barnieh, Rachel Beckerman, Sushanth Jeyakumar, et al.
Journal of Comparative Effectiveness Research|February 6, 2024
Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in GreeceEmmanouil Sinakos, Nandita Kachru, Christos Tsoulas, et al.
Journal of Medical Economics|April 27, 2021
Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare populationDeborah A Fisher, Jordan J Karlitz, Sushanth Jeyakumar, et al.
Journal of Medical Economics|February 23, 2026
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United StatesAndrea Lopez, Michael Gargano, Hongbo Yang, et al.
Journal of Medical Economics|April 9, 2026
Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent <b><i>β</i></b>-thalassemia in the United StatesChuka Udeze, Michael Gargano, Hongbo Yang, et al.
MDM Policy & Practice|March 31, 2025
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in TaiwanElise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, et al.
Pain Medicine (Malden, Mass.)|April 22, 2026
Real World Treatment Patterns Among Patients with Painful Diabetic Peripheral Neuropathy in the United StatesNathaniel M Schuster, Sushanth Jeyakumar, Ann M Menzie, et al.
Scientific Reports|June 10, 2022
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysisRachel Beckerman, Andrea Gori, Sushanth Jeyakumar, et al.
Journal of Medical Economics|December 18, 2025
Societal burden of the US opioid epidemic over the next 15 years and the potential impact of effective non-opioid treatments for painJeromie M Ballreich, Sushanth Jeyakumar, Kenna Garrison, et al.
Journal of Medical Economics|May 5, 2026
The incidence of opioid use disorder among people with acute and chronic pain managed with prescription opioids in the United States: economic and societal burdenAndrew J Schoenfeld, Sushanth Jeyakumar, Jessica Morlando Geiger, et al.
Pageof 2